HMOX1 and neuroblastoma: Barbagallo et al. described that increased HO-1 gene expression and enzymatic activity drive resistance to carfilzomib in neuroblastoma cells, while cotreatment with carfilzomib and LS1/71, a noncompetitive inhibitor of HO-1, triggered cell apoptosis with significantly activated proapoptotic BAX gene expression and reduced antiapoptotic BFAR gene expression [192].